2 completed, 2 withdrawn, 1 active not recruiting, 1 recruiting. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 2, Withdrawn 2, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Withdrawn 2, Active not recruiting 1 |
Follow Progressive Disease: new trials by email Literature Review of Progressive Disease trials Research Report on Progressive Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET Lutathera - Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor | Phase 2 | Recruiting | Institut du Cancer de Montpellier - Val d'Aurelle | 146 | 2021-10-18 | 2026-06-04 |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 23 | 2020-03-04 | 2026-02-27 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recombinant EphB4-HSA Fusion Protein - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Unknown | Northwestern University | 14 | 2019-09-20 | 2022-04-27 |
| Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Avelumab, Axitinib - Metastatic Adenoid Cystic Carcinoma, Progressive Disease | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2019-07-22 | 2024-10-18 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Cetuximab, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2019-06-14 | 2026-11-10 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive BKM120 - Head and Neck Neoplasms, Neoplasm Metastasis | Phase 2 | Completed | Centre Leon Berard | 58 | 2013-01-01 | 2019-06-24 |
Disease Progression (8) · Burkitt Lymphoma (1) · Carcinoma, Adenoid Cystic (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1) · Neuroendocrine Tumors (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1)
Disease Attributes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Neoplasms (7) · Neoplasms by Histologic Type (4) · Hemic and Lymphatic Diseases (3) · Neoplasms by Site (3) · Hematologic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoproliferative Disorders (2) · Neoplastic Processes (2)
Cyclophosphamide (2) · fludarabine (2) · Axitinib (1) · Cetuximab (1) · Hydroxychloroquine (1) · Interleukin 1 Receptor Antagonist Protein (1) · NVP-BKM120 (1) · Nivolumab (1) · Receptors, Interleukin-6 (1) · avelumab (1) · axicabtagene ciloleucel (1) · devimistat (1) · encorafenib (1) · fludarabine phosphate (1) · lutetium Lu 177 dotatate (1)
M.D. Anderson Cancer Center (3) · Centre Leon Berard (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Jonsson Comprehensive Cancer Center (1) · Northwestern University (1) · Wake Forest University Health Sciences (1)
United States (6) · France (2)
Bayard Powell, MD (1) · Deshayes Emmanuel, PHD (1) · Jin S Im (1) · John M Timmerman, MD (1) · Maha H Hussain, M.D. (1) · Renata Ferrarotto (1) · Van K Morris (1)
P30CA012197 (1), P30CA016672 (1), P30CA060553 (1)